Capitalink Ltd. Exits Position in Clearmind Medicine Inc. (CMND)

Capitalink Ltd. filed a Schedule 13G/A (Amendment No. 3) with the SEC on May 15, 2026, regarding its holdings in Clearmind Medicine Inc. (CMND). The filing indicates that as of March 31, 2026, Capitalink Ltd. no longer holds any common shares of the issuer, reporting a beneficial ownership of 0 shares, representing 0.00% of the class. This marks a complete exit from its previous position in the company. Capitalink Ltd. is an Israeli-based entity, and the filing was signed by CEO Lavi Krasney. The document confirms that the securities were not held for the purpose of influencing or changing the control of the issuer. Clearmind Medicine Inc. is headquartered in Vancouver, British Columbia, and specializes in biotech/pharmaceutical developments. This amendment serves to formally notify the SEC and the public that the reporting person has ceased to be a beneficial owner of more than five percent of the class of securities.